PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets) is now authorized for use in Canada

PAXLOVID (nirmatrelvir tablets; ritonavir tablets) is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

PAXLOVID is not authorized:

For initiation of treatment in patients requiring hospitalization due to severe or critical COVID-19.
For pre-exposure or post-exposure prophylaxis for prevention of COVID-19.
For use longer than 5 consecutive days.

PAXLOVID Product Monograph

View the full Product Monograph, which includes dosing, clinical data, and safety information.

Click here

PAXLOVID Patient Medication Information

View the full Patient Medication Information, which contains important information for the patient about how to take PAXLOVID and what to expect from treatment.

Click here

PAXLOVID Health Product Risk Communication (January 17, 2022)

View the Health Product Risk Communication, which includes a description of the health risk associated with PAXLOVID, what health professionals can do, and any other important information.

Click here

PAXLOVID Health Product Risk Communication (July 6, 2022)

View the Health Product Risk Communication, which includes a description of the health risk associated with PAXLOVID, what health professionals can do and any other important information.

Click here